The HA-1A monoclonal antibody for gram-negative sepsis

Raul J. Gazmuri, Carter Mecher, Max Harry Weil, Craig P. Tanio, Harold I. Feldman, J. Carlet, G. Offenstadt, C. Chastang, F. Doyon, C. Brun-Buisson, J. F. Dhainaut, B. Schlemmer, L. Gutmann, Gregory A. Schmidt, Harry B. Peled, S. Mackenzie, J. Kinsella, Lowell S. Young, Kenneth J. Gorelick, Jean Daniel BaumgartnerDidier Heumann, Michel Pierre Glauser, Elizabeth J. Ziegler, Charles J. Fisher, Charles L. Sprung, Craig R. Smith, Richard C. Straube, Jerald C. Sadoff, R. Phillip Dellinger, Sheldon M. Wolff

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: Ziegler and collaborators (Feb. 14 issue)1 recently reported on an impressive reduction in 28-day mortality, from 49 percent to 30 percent, in a subgroup of patients who had bacteremia due to gram-negative bacilli. The patients were treated with human anti—lipid A monoclonal antibody early in the course after the onset of symptoms. Patients with sepsis or bacteremia caused by microorganisms other than gram-negative bacilli received no measurable benefit. These results prompted the investigators to recommend the therapy as routine treatment for patients with clinical signs of bacteremia, provided that a gram-negative organism was suspected as the cause.

Original languageEnglish (US)
Pages (from-to)279-283
Number of pages5
JournalNew England Journal of Medicine
Volume325
Issue number4
DOIs
StatePublished - Jul 25 1991

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'The HA-1A monoclonal antibody for gram-negative sepsis'. Together they form a unique fingerprint.

Cite this